RCKT Rocket Pharmaceuticals Inc

$RCKT you do realize, management doesn't control the stock of the company right..... Its 95% institutionally owned, which means when the 1% decides they want it to run, they will make it run out of no where, no based on anything else. So you can be angry at everyone, but you are not yelling at the right plp. $RCKT is poised to run to $30-$50 and $90-$100 with BO, the science is there, the approvals are there, the lineup is there.... Only thing investors need is patience, why.... because the markets reward the patient, not the greedy who want everything NOW!, TODAY! Invest in the science and company. And learn to control the greed and ego.

$RCKT RCKT has $283 million in cash/cash equivalents and market cap is now 295 million. Interesting..

$RCKT Blackrock inc. paid $3.86 per share that they bought september 2th, 2026 If they are not worried, why should you be ? ❤️❤️🫡❤️❤️

$RCKT 13 days left before RCKT make their conference to shareholders about Danon. I think that we are getting closer for a buyout. ❤️

$RCKT One thing that I really like about the company is that the cardiac story isn’t riding on one program. They’re building across Danon, PKP2 and BAG3 cardiomyopathies

$RCKT total trash Rocket Pharma management is honestly trash. They should have pushed much harder for a BLA given the extensive clinical history with RP-A501, including years of functional and biomarker data and 6 patients already dosed in the pivotal trial before the hold. Add the lower-dose regimen specifically designed to address the safety issues, and there was a strong basis to argue for a more flexible regulatory path in such an ultra-rare disease. Instead, Rocket's painfully slow execution has left us needing 9 additional patients. Promising science, but absolutely terrible execution

$RCKT i traded this stock in the twenties (at a loss) not that long ago. Fuck happend here?

$RCKT I think this is an interesting stock leading up to the 10/06/2026 meeting. Elaborating on the FDA news could be a nice catalyst. 🚀🍌🦍

$RCKT honestly, i hate this market. Trump and his cronies are propping it up, spreading lies and diverting attention from every negative indicator to keep the market from collapsing. Still, this one looks like a bargain to me.

$RCKT Blackrock inc. have $25,752,681 millions in Rocket Pharmaceuticals. Now, that is a lot of money to invest in a small biotech. They know what they are doing. They are not moving, no matter what the share price is. At the end of the race they know that they will have a winner. Blackrock is worth 176.49 billions. That is just one of the investors. 🥰

$RCKT There is a lot of misinformation about RCKT on this board. I don’t know whether this is intentional or simply due to a lack of knowledge about the company. Rather than replying to posts, here is a response: Let’s stop pretending everything is fine. RCKT has fallen roughly 23% since Sept 17 on heavy volume and is approaching its 52-week low. This is not simply “minor market adjustments.” The market is disappointed that the Oct 6 Danon update will not provide new efficacy data. Gaurav Shah said at Morgan Stanley that it is simply too early. RCKT has not sold a pipeline project. The $180M came from monetizing the Priority Review Voucher awarded after KRESLADI’s FDA approval. The buyer remains confidential. The real problem is the timeline: dosing is expected to finish around mid-2027, while pivotal 12-month efficacy data may not be available until 2028. At the current share price, a capital raise could be highly dilutive. These are real issues—not simply “minor market adjustments.”

$RCKT In an effort to alleviate all fear and apprehension of potential investors of RCKT stock, I spent the last 2 days telling people at my local grocery store about all of the wonderful things going on at this company. Although most customers simply walked away from me, I did get quite a few perplexing and quizzical stares, leading me to believe that they were seriously considering purchasing some shares.

$RCKT What in bloody tarnations wreaked holy havoc on this badly beleaguered stock today?

$RCKT is one I’m watching closely here. They already have an FDA-approved gene therapy, but the bigger catalyst could be Danon disease.

$RCKT - This is an unfortunate but expected price action. The dosing for the new 9 patients wont conclude until mid-late 2027 then the efficiency data from that is even longer - so you are looking at 2028. So the stock is doing what it should be doing ......

$RCKT an interesting tidbit I've seen is that the recalibrated danon dose is using the same commercial grade product they plan to move forward with. It's nice to see the trial getting closer to the eventual real world setup

$RCKT There was one slide on the RTW Biotech Opportunites Ltd's Results presentation this morning that gave a very prominent position to Rocket. The slide about how they create companies. I thought this was quite noticeable. Compared to the other companies they showed on the same slide which have generated huge value for them, Rocket looked rather good. I took it that despite the huge drop in Rocket's share price from recent years, they are becoming more proud of it: which I take as a sign that they can see value realisation coming.

$RCKT Nasty price action over the last couple of days. And yet on the operational front things have been going well all things considered: or at least I thought they were. Has something happened?

$RCKT A good pick if you're looking for something in the space that won't need to dilute for a while.

$RCKT having to repeatedly mute people when volume picks up in either trading direction is tiring. Interest rates are up so riskier pre-commercial stocks are down. $RCKT will need until mid-2027 to enrol all 12 patients before submitting a rolling BLA request as 12 months follow up data is required. Short interest is increasing and catalyst investors are leaving as there will be no expedited BLA and no major catalysts until mid-2028. RTW is still the primary institutional backer at 19% Cash floor is around $2.58 but this will continue to drop and Kresladi sales won’t do much so a raise will be needed before any PDUFA date arrives. $RCKT still has the first and only treatment for Danon, they also have their own manufacturing facilities already paid for. This is not a get rich quick stock but all being well it’s a get very rich stock come 2029/2030 come first year commercialisation is r come buyout. Choose whether you want to invest but decide on facts